Health
U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
WHIPPANY, N.J., May 18, 2026--U.S. FDA Grants Priority Review to sNDA for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated NSCLC
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":400,"url":"https://media.zenfs.com/en/business-wire.com/4a5b3a33a70fe9c32e2259a8ed377408"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/S_cM4L1xYs0EDw27fVHRYA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwNQ--/https://media.zenfs.com/en/business-wire.com/4a5b3a33a70fe9c32e2259a8ed377408","width":400,"height":400},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/PPWjTV9M5qUq7.0EvG_M4Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTY0MA--/https://media.zenfs.com/en/business-wire.com/4a5b3a33a70fe9c32e2259a8ed377408","width":400,"height":400}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Regulatory submission for first-line use of HYRNUO is based on results from the ongoing Phase I/II SOHO-01 trial evaluating the efficacy and safety in patients with advanced HER2-mutated non-small cell lung cancer (NSCLC) who have not received prior therapy","length":257,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The U.S. Food and Drug Administration (FDA) grants Priority Review designation for the evaluation of medicines that, if approved, would provide significant improvement in the safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition1","length":265,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":522,"olType":false},{"type":"text","content":"WHIPPANY, N.J., May 18, 2026--(BUSINESS WIRE)--Bayer announced today that the U.S. Food and Drug Administration (FDA) has granted HYRNUO® (sevabertinib) Priority Review status for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations in patients with no prior therapy. HYRNUO is not currently approved in this first-line setting.","length":470,"tagName":"p"},{"type":"text","content":"In November 2025, HYRNUO received U.S. FDA accelerated approval for patients with locally advanced or metastatic NSCLC whose tumors have HER2 TKD activating mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.2 This indication is approved under accelerated approval based on objective response rate (ORR) and ...